Association between physical activity and dementia’s risk factors in patients with Parkinson’s disease Neurology and Preclinical Neurological Studies - Original Article First Online: 12 February 2019 Abstract
Evidence suggests that physical activity (PA) exerts beneficial effects on neurodegenerative processes, either as symptomatic relief or disease-modifying strategy. Actually, it may represent a viable neuroprotective intervention in Parkinson’s disease dementia (PDD), a severe, frequent, and untreatable complication of Parkinson’s disease (PD). According to such hypothesis, this cross-sectional study tested, in PD patients, the association between levels of PA and well-known risk factors for PDD, such as mood disorders and amyloid-β42 CSF content. Amount of PA was measured by the International Physical Activity Questionnaires—Short Form (IPAQ–SF) in 128 cognitively intact PD patients and correlated with the Hamilton-Depression (HAM-D) and the Hamilton-Anxiety (HAM-A) scores; in a homogenous subgroup of 40 patients, it was further correlated with a panel of CSF biomarkers, including amyloid-β42, total α-synuclein, total, and phosphorylated tau. The statistical model was corrected for the main potential confounding factors (motor impairment, dopaminergic treatment, disease duration, age, and sex). Both the HAM-A and HAM-D scores, as well as the Aβ42 CSF content, improved in parallel with the increase of the total week amount of PA. Although with several limitations, we preliminarily demonstrated that a high level of PA is associated with a more favourable profile of PDD risk factors, in terms of both mood disturbances and CSF markers of neurodegeneration. However, confirmative studies are necessary to validate the efficacy of PA as protective intervention for PDD.
Keywords Parkinson’s disease Physical activity Parkinson’s disease dementia Frailty CSF biomarkers Neuroprotection
Mohammad Alwardat and Tommaso Schirinzi have contributed equally to this work.
Notes Compliance with ethical standards Conflict of interest
The authors declare that they have no conflict of interest.
The “Tor Vergata University Hospital” Ethics Committee approved the study; the study also respected the ethical standards of Helsinki declaration. Participants provided informed consent.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Artusi CA, Mishra M, Latimer P et al (2018) Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. Parkinson Relat Disord 46:S53–S56.
https://doi.org/10.1016/j.parkreldis.2017.07.022 CrossRef Google Scholar
Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Publ Gr 6:131–144.
https://doi.org/10.1038/nrneurol.2010.4 Google Scholar
Blennow K, Biscetti L, Eusebi P, Parnetti L (2016) Cerebrospinal fluid biomarkers in Alzheimer’s and Parkinson’s diseases-from pathophysiology to clinical practice. Mov Disord 31:836–847.
https://doi.org/10.1002/mds.26656 CrossRef Google Scholar
Compta Y, Parkkinen L, O’Sullivan SS et al (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134:1493–1505.
https://doi.org/10.1093/brain/awr031 CrossRef Google Scholar
Cusso ME, Donald KJ, Khoo TK (2016) The impact of physical activity on non-motor symptoms in Parkinson’s disease: a systematic review. Front Med 3:35.
https://doi.org/10.3389/fmed.2016.00035 CrossRef Google Scholar
Dissanayaka NNW, Lawson RA, Yarnall AJ et al (2017) Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson’s disease. Parkinson Relat Disord 36:63–68.
https://doi.org/10.1016/j.parkreldis.2017.01.001 CrossRef Google Scholar
Dorr A, Sahota B, Chinta LV et al (2012) Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer’s disease. Brain 135:3039–3050.
https://doi.org/10.1093/brain/aws243 CrossRef Google Scholar
Fava GA, Kellner R, Munari F, Pavan L (1982) The Hamilton depression rating scale in normals and depressives. Acta Psychiatr Scand 66:26–32
CrossRef Google Scholar
Gratwicke J, Jahanshahi M, Foltynie T (2015) Parkinson’s disease dementia: a neural networks perspective. Brain 138:1454–1476.
https://doi.org/10.1093/brain/awv104 CrossRef Google Scholar
Halliday GM, Leverenz JB, Schneider JS, Adler CH (2014) The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord 29:634–650.
https://doi.org/10.1002/mds.25857 CrossRef Google Scholar
Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
CrossRef Google Scholar
Huang T, Larsen KT, Ried-Larsen M et al (2014) The effects of physical activity and exercise on brain-derived neurotrophic factor in healthy humans: a review. Scand J Med Sci Sports 24:1–10.
https://doi.org/10.1111/sms.12069 CrossRef Google Scholar
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
CrossRef Google Scholar
Jessen NA, Munk ASF, Lundgaard I, Nedergaard M (2015) The glymphatic system: a beginner’s guide. Neurochem Res 40:2583–2599.
https://doi.org/10.1007/s11064-015-1581-6 CrossRef Google Scholar
Johar I, Mollenhauer B, Aarsland D (2017) Cerebrospinal fluid biomarkers of cognitive decline in Parkinson’s disease. Int Rev Neurobiol 132:275–294.
https://doi.org/10.1016/bs.irn.2016.12.001 CrossRef Google Scholar
Joling M, van den Heuvel OA, Berendse HW et al (2018) Serotonin transporter binding and anxiety symptoms in Parkinson’s disease. J Neurol Neurosurg Psychiatry 89:89–94.
https://doi.org/10.1136/jnnp-2017-316193 CrossRef Google Scholar
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912.
https://doi.org/10.1016/S0140-6736(14)61393-3 CrossRef Google Scholar
Kotagal V, Spino C, Bohnen NI et al (2018) Serotonin, β-amyloid, and cognition in Parkinson disease. Ann Neurol.
https://doi.org/10.1002/ana.25236 Google Scholar
Kulisevsky J, Oliveira L, Fox SH (2018) Update in therapeutic strategies for Parkinsonʼs disease. Curr Opin Neurol.
https://doi.org/10.1097/WCO.0000000000000579 Google Scholar
Law LL, Rol RN, Schultz SA et al (2018) Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer’s disease. Alzheimer Dement (Amsterdam Netherlands) 10:188–195.
https://doi.org/10.1016/j.dadm.2018.01.001 Google Scholar
Liu PZ, Nusslock R (2018) Exercise-mediated neurogenesis in the Hippocampus via BDNF. Front Neurosci 12:52.
https://doi.org/10.3389/fnins.2018.00052 CrossRef Google Scholar
Mak MK, Wong-Yu IS, Shen X, Chung CL (2017) Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol 13:689–703.
https://doi.org/10.1038/nrneurol.2017.128 CrossRef Google Scholar
Maltese M, Stanic J, Tassone A et al (2018) Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum. Elife.
https://doi.org/10.7554/eLife.33331 Google Scholar
Mannocci A, Thiene D, Di Cimmuto A, Del et al (2010) International Physical Activity Questionnaire: validation and assessment in an Italian sample. Ital J Public Health.
https://doi.org/10.2427/5694 Google Scholar
Marinus J, Zhu K, Marras C et al (2018) Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol 17:559–568.
https://doi.org/10.1016/S1474-4422(18)30127-3 CrossRef Google Scholar
Martorana A, Di Lorenzo F, Belli L et al (2015) Cerebrospinal fluid Aβ42 levels: when physiological become pathological state. CNS Neurosci Ther 21:921–925.
https://doi.org/10.1111/cns.12476 CrossRef Google Scholar
Measso G, Cavarzeran F, Zappalà G et al (1993) The mini-mental state examination: normative study of an Italian random sample. Dev Neuropsychol 9:77–85.
https://doi.org/10.1080/87565649109540545 CrossRef Google Scholar
Moore KM, Girens RE, Larson SK et al (2016) A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer’s disease. Neurobiol Dis 85:218–224.
https://doi.org/10.1016/j.nbd.2015.11.004 CrossRef Google Scholar
Ngandu T, Lehtisalo J, Solomon A et al (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385:2255–2263.
https://doi.org/10.1016/S0140-6736(15)60461-5 CrossRef Google Scholar
Pietrelli A, Matkovic L, Vacotto M et al (2018) Aerobic exercise upregulates the BDNF-Serotonin systems and improves the cognitive function in rats. Neurobiol Learn Mem.
https://doi.org/10.1016/j.nlm.2018.05.007 Google Scholar
Politis M, Niccolini F (2015) Serotonin in Parkinson’s disease. Behav Brain Res 277:136–145.
https://doi.org/10.1016/j.bbr.2014.07.037 CrossRef Google Scholar
Ryan SM, Kelly ÁM (2016) Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer’s disease. Ageing Res Rev 27:77–92.
https://doi.org/10.1016/j.arr.2016.03.007 CrossRef Google Scholar
Sancesario GM, Bernardini S (2015) How many biomarkers to discriminate neurodegenerative dementia? Crit Rev Clin Lab Sci 52:314–326.
https://doi.org/10.3109/10408363.2015.1051658 CrossRef Google Scholar
Schirinzi T, Sancesario GM, Ialongo C et al (2015) A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. Front Neurol 6:86.
https://doi.org/10.3389/fneur.2015.00086 CrossRef Google Scholar
Schirinzi T, Madeo G, Martella G et al (2016) Early synaptic dysfunction in Parkinson’s disease: Insights from animal models. Mov Disord 31:802–813.
https://doi.org/10.1002/mds.26620 CrossRef Google Scholar
Schirinzi T, Di Lazzaro G, Sancesario GM et al (2017) Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease. J Neural Transm.
https://doi.org/10.1007/s00702-017-1786-8 Google Scholar
Schirinzi T, Di Lorenzo F, Sancesario GM et al (2018a) Amyloid-mediated cholinergic dysfunction in motor impairment related to Alzheimer’s disease. J Alzheimer’s Dis 64:525–532.
https://doi.org/10.3233/JAD-171166 CrossRef Google Scholar
Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018b) CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. Parkinson Relat Disord.
https://doi.org/10.1016/j.parkreldis.2018.10.018 Google Scholar
Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018c) Clinical value of CSF amyloid-beta-42 and tau proteins in progressive supranuclear palsy. J Neural Transm.
https://doi.org/10.1007/s00702-018-1893-1 Google Scholar
Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018d) Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. J Neural Transm.
https://doi.org/10.1007/s00702-018-1842-z Google Scholar
Sleiman SF, Chao MV (2015) Downstream consequences of exercise through the action of BDNF. Brain Plast 1:143–148.
https://doi.org/10.3233/BPL-150017 CrossRef Google Scholar
Tarumi T, Zhang R (2018) Cerebral blood flow in normal aging adults: cardiovascular determinants, clinical implications, and aerobic fitness. J Neurochem 144:595–608.
https://doi.org/10.1111/jnc.14234 CrossRef Google Scholar
Wang H-F, Yu J-T, Tang S-W et al (2015) Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 86:135–143.
https://doi.org/10.1136/jnnp-2014-307659 CrossRef Google Scholar Copyright information
© Springer-Verlag GmbH Austria, part of Springer Nature 2019